Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine +

Victory Square Technologies Reports Fiscal 2025 Results Highlighting Platform Scaling, Healthcare Infrastructure Growth and Portfolio Momentum

Hydreight Revenue Guidance Confirmed, But Execution Risk Remains on 4x Growth Target

Executive Summary
  • Victory Square Technologies reported Fiscal 2025 audited financial results showing consolidated revenue of $35.4 million, a 121% increase year-over-year from FY2024 ($16.04M).
  • Hydreight Technologies Inc., the primary operating subsidiary, contributed significantly to this growth with adjusted EBITDA turning positive at $2.5 million compared to $136K in FY2024.
  • The company reiterated forward revenue guidance for Fiscal 2026 of approximately $150 million for Hydreight Technologies, a figure previously disclosed in February 2026.
  • Cash and marketable securities increased to $22.0 million with working capital at $15.0 million, indicating improved liquidity compared to prior periods.
  • Operational metrics show over 11,000 licenses signed for the VSDHOne healthcare platform and a distribution of Yocale.ai shares completed in April 2026.
  • Pawsible Ventures launched a $10M venture fund targeting pet health infrastructure, expanding the company's portfolio beyond digital health.
Material Impact
  • The Fiscal 2025 revenue beat ($35.4M vs FY2024 $16.04M) validates the growth trajectory but does not introduce new upside beyond expectations set in February 2026 when the $150M guidance was first issued.
  • Profitability improvement (Adjusted EBITDA of $2.5M) is a positive confirmation that Hydreight has reached operational leverage, reducing the risk of immediate capital dilution for operations.
  • The reiterated $150M FY2026 guidance represents a 4x increase from current run rates; while confirmed by management, this remains an aggressive target with significant execution risk if partner activity does not scale as projected.
  • Since the core catalyst (the $150M guidance) was already public in February and March news releases, this earnings release is largely confirmatory rather than transformative for valuation.
  • The stock price has corrected from September highs ($0.98) to current levels ($0.72), suggesting the market may have priced in the growth expectations earlier; this news reinforces the thesis but does not justify a new breakout without further catalysts.
VST · Price
Company Overview
  • Company: Victory Square Technologies Inc. (CSE: VST).
  • Flagship Project: Hydreight Technologies Inc., a digital health infrastructure platform operating across 50 U.S. states.
  • Platform: VSDHOne, a modular compliance framework for telehealth and pharmacy fulfillment supporting GLP-1s, TRT, peptides, and other categories.
  • Portfolio: Includes Insu Therapeutics (biotech), Pawsible Ventures (pet health fund), SafeTest Diagnósticos (Brazil diagnostics), and XR Immersive Technologies.
  • Business Model: Revenue generated through platform licensing, transaction fees on product orders placed, and venture investments in portfolio companies.
Read the original news release →

More from Victory Square Technologies Inc.